Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
QDEL | US
-1.37
-7.94%
Healthcare
Diagnostics & Research
30/06/2024
06/04/2026
15.88
17.19
17.35
15.72
QuidelOrtho Corporation focuses on the development and manufacture of diagnostic testing technologies and solutions. The company operates through Labs Transfusion Medicine Point-of-Care and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests which measure proteins as they act as antigens in the spread of disease antibodies in the immune response spurred by disease or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices hospitals clinical laboratories reference laboratories urgent care clinics universities retail clinics pharmacies wellness screening centers blood banks and donor centers as well as for individual non-professional and over-the-counter use. It operates in North America Europe the Middle East Africa China and internationally. The company was founded in 1979 and is headquartered in San Diego California.
View LessLow Market Beta (-0.4 to 0.8)
Value Stock (Price to Book < 3)
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Debt to Equity (> 0.75)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
85.5%1 month
89.3%3 months
77.7%6 months
76.1%-
12.64
0.85
0.87
0.41
7.61
1.89
7.19
589.70M
1.07B
1.07B
-
-4.66
-77.10
-4.20
-45.48
5.16
9.08
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
3.10
Range1M
5.79
Range3M
21.13
Rel. volume
0.86
Price X volume
26.28M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| NeoGenomics Inc | NEO | Diagnostics & Research | 8.02 | 1.03B | 0.25% | n/a | 66.22% |
| CareDx Inc | CDNA | Diagnostics & Research | 17.82 | 939.83M | -2.68% | n/a | 11.88% |
| Check-Cap Ltd | CHEK | Diagnostics & Research | 136 | 795.49M | 0.74% | n/a | 0.00% |
| CASTLE BIOSCIENCES INC | CSTL | Diagnostics & Research | 24.73 | 685.93M | -0.44% | n/a | 5.94% |
| Atossa Genetics Inc | ATOS | Diagnostics & Research | 5.15 | 647.65M | -4.01% | n/a | 0.00% |
| Fulgent Genetics Inc | FLGT | Diagnostics & Research | 16.42 | 497.47M | -2.38% | n/a | 1.18% |
| Personalis Inc | PSNL | Diagnostics & Research | 6.58 | 433.85M | 0.00% | n/a | 41.56% |
| Varex Imaging Corporation | VREX | Diagnostics & Research | 10.56 | 431.49M | 0.57% | 16.69 | 80.92% |
| Myriad Genetics Inc | MYGN | Diagnostics & Research | 4.67 | 424.13M | -1.68% | n/a | 0.00% |
| National Research Corporation | NRC | Diagnostics & Research | 17.33 | 413.69M | 0.99% | 16.76 | 105.03% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Winnebago Industries Inc | WGO | Recreational Vehicles | 31.52 | 912.66M | 3.82% | 22.53 | 56.33% |
| HUYA Inc | HUYA | Media - Diversified | 3.23 | 731.18M | -5.28% | n/a | 0.00% |
| Janus International Group Inc. | JBI | Building Products & Equipment | 5 | 726.61M | 1.63% | 11.62 | 116.21% |
| Fox Factory Holding Corp | FOXF | Recreational Vehicles | 16.15 | 673.18M | -3.70% | 42.05 | 64.69% |
| Latham Group Inc. | SWIM | Building Products & Equipment | 5.28 | 610.25M | 1.73% | 65.18 | 77.00% |
| The Marcus Corporation | MCS | Media - Diversified | 18.44 | 593.28M | 3.25% | n/a | 83.32% |
| Ennis Inc | EBF | Building Products & Equipment | 21.77 | 566.10M | 0.37% | 13.28 | 2.28% |
| Malibu Boats Inc | MBUU | Recreational Vehicles | 24.28 | 485.37M | -0.82% | n/a | 1.50% |
| AMC Entertainment Holdings Inc | AMC | Media - Diversified | 1.26 | 455.31M | 12.50% | n/a | -511.14% |
| MCBC Holdings Inc | MCFT | Recreational Vehicles | 20.29 | 336.96M | -0.05% | 34.27 | 26.82% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 7.61 | 12.67 | Cheaper |
| Ent. to Revenue | 1.89 | 44.00 | Cheaper |
| PE Ratio | - | 40.09 | - |
| Price to Book | 0.85 | 77.50 | Cheaper |
| Dividend Yield | - | 1.18 | - |
| Std. Deviation (3M) | 77.72 | 59.59 | Riskier |
| Debt to Equity | 0.87 | -14.36 | Expensive |
| Debt to Assets | 0.41 | 0.34 | Expensive |
| Market Cap | 1.07B | 13.71B | Emerging |